MX2023008634A - Análogos de rapamicina y usos de estos. - Google Patents
Análogos de rapamicina y usos de estos.Info
- Publication number
- MX2023008634A MX2023008634A MX2023008634A MX2023008634A MX2023008634A MX 2023008634 A MX2023008634 A MX 2023008634A MX 2023008634 A MX2023008634 A MX 2023008634A MX 2023008634 A MX2023008634 A MX 2023008634A MX 2023008634 A MX2023008634 A MX 2023008634A
- Authority
- MX
- Mexico
- Prior art keywords
- rapamycin analogs
- rapamycin
- analogs
- compositions
- methods
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140523P | 2021-01-22 | 2021-01-22 | |
| US202163202524P | 2021-06-15 | 2021-06-15 | |
| PCT/US2022/070308 WO2022159976A1 (en) | 2021-01-22 | 2022-01-24 | Rapamycin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008634A true MX2023008634A (es) | 2023-10-10 |
Family
ID=82549982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008634A MX2023008634A (es) | 2021-01-22 | 2022-01-24 | Análogos de rapamicina y usos de estos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220267352A1 (https=) |
| EP (1) | EP4281463A4 (https=) |
| JP (1) | JP2024503898A (https=) |
| KR (1) | KR20230136625A (https=) |
| AU (1) | AU2022209863A1 (https=) |
| BR (1) | BR112023014287A2 (https=) |
| CA (1) | CA3209086A1 (https=) |
| MX (1) | MX2023008634A (https=) |
| WO (1) | WO2022159976A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3914245A4 (en) | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC-1 MODULATORS AND USES THEREOF |
| WO2021195599A1 (en) | 2020-03-27 | 2021-09-30 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935110B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| JP2010500286A (ja) * | 2006-07-25 | 2010-01-07 | アボット・ラボラトリーズ | 結晶形態のラパマイシン類似体 |
| WO2011130232A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| EP2601201B1 (en) * | 2010-08-04 | 2014-09-24 | Meril Life Sciences Pvt. Ltd. | Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| IL314362A (en) * | 2018-06-15 | 2024-09-01 | Janssen Pharmaceutica Nv | Rapamycin analogs and their uses |
| WO2020076738A2 (en) * | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| EP3914245A4 (en) * | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC-1 MODULATORS AND USES THEREOF |
| KR20220128345A (ko) * | 2019-12-05 | 2022-09-20 | 아나쿠리아 테라퓨틱스, 인코포레이티드 | 라파마이신 유사체 및 이의 용도 |
-
2022
- 2022-01-24 JP JP2023544070A patent/JP2024503898A/ja active Pending
- 2022-01-24 CA CA3209086A patent/CA3209086A1/en active Pending
- 2022-01-24 US US17/648,750 patent/US20220267352A1/en not_active Abandoned
- 2022-01-24 AU AU2022209863A patent/AU2022209863A1/en not_active Abandoned
- 2022-01-24 MX MX2023008634A patent/MX2023008634A/es unknown
- 2022-01-24 BR BR112023014287A patent/BR112023014287A2/pt unknown
- 2022-01-24 KR KR1020237027812A patent/KR20230136625A/ko active Pending
- 2022-01-24 EP EP22743426.3A patent/EP4281463A4/en active Pending
- 2022-01-24 WO PCT/US2022/070308 patent/WO2022159976A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022209863A1 (en) | 2023-09-07 |
| US20220267352A1 (en) | 2022-08-25 |
| EP4281463A1 (en) | 2023-11-29 |
| KR20230136625A (ko) | 2023-09-26 |
| JP2024503898A (ja) | 2024-01-29 |
| EP4281463A4 (en) | 2025-07-23 |
| WO2022159976A1 (en) | 2022-07-28 |
| BR112023014287A2 (pt) | 2023-11-21 |
| CA3209086A1 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007852A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2022007576A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2021006154A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
| MX2022007841A (es) | Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos. | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CO2023006818A2 (es) | Degradadores de irak y sus usos | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
| CR20230103A (es) | Análogos de rapamicina ligados a c40, c28 y c32 como inhibidores de mtor | |
| PH12023500023A1 (en) | Cdk2 degraders and uses thereof | |
| MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
| MX2023011933A (es) | Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos. | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| EA202092909A1 (ru) | Новый бензодиазепин, его производные и применение | |
| CO2025009897A2 (es) | Degradadores de irak y usos de los mismos | |
| BR112022020451A2 (pt) | Composição de fragrância | |
| CO2020006542A2 (es) | Profármacos de creatina, composiciones y métodos de uso de estos | |
| MX2023008634A (es) | Análogos de rapamicina y usos de estos. | |
| MX2022007190A (es) | Analogos de cistina diamida para la cistinuria. | |
| CO2025016192A2 (es) | Moléculas y métodos de uso de estas |